Emerging data suggest this peptide, a dual activator targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , appears to offer a notable development for body treatment. Preliminary clinical trials have indicated considerable decreases in visceral fat , possibly exceeding other body composition treatments. Nevertheless ,